Implications of a circulating vaccine-derived poliovirus in Nigeria

New England Journal of Medicine

Volumn 362, Issue 25, 2010, Pages 2360-2369

  Jenkins, Helen E ^a   Aylward, R Bruce ^b   Gasasira, Alex ^c   Donnelly, Christl A ^a   Mwanza, Michael ^c   Corander, Jukka ^g   Garnier, Sandra ^b   Chauvin, Claire ^b   Abanida, Emmanuel ^d   Pate, Muhammad Ali ^d   Adu, Festus ^e   Baba, Marycelin ^f   Grassly, Nicholas C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c WHO Nigeria   (Nigeria)

^d NATIONAL PRIMARY HEALTH CARE DEVELOPMENT AGENCY   (Nigeria)

^e UNIVERSITY OF IBADAN   (Nigeria)

^f UNIVERSITY OF MAIDUGURI   (Nigeria)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FECES; FEMALE; FLACCID PARALYSIS; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; NIGERIA; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE;

EID: 77953927000     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0910074     Document Type: Article

References (28)

1. Global Polio Eradication Initiative website. (Accessed May 28, 2010, at http://www.polioeradication.org/.)
2. Resurgence of wild poliovirus types 1 and 3 in 15 African countries, January 2008-March 2009. Wkly Epidemiol Rec 2009;84:133-40.
3. Global update on vaccine-derived polioviruses, January 2006-August 2007. Wkly Epidemiol Rec 2007;82:337-43.
4. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008;3(10):e3433.
5. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003;77:8366-77.
6. Agol VI. Vaccine-derived polioviruses. Biologicals 2006;34:103-8.
7. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. Vaccination against polio should not be stopped. Nat Rev Microbiol 2007;5: 952-8.
8. Arita I, Nakane M, Fenner F. Public health: is polio eradication realistic? Science 2006;312:852-4.
9. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001;50:222-4.
10. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001; 33:531-41.
11. Jenkins HE, Aylward RB, Gasasira A, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med 2008;359:1666-74.
12. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007;369:1356-62.
13. El-Sayed N, El-Gamal Y, Abbassy A-A, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008; 359:1655-65.
14. Advisory Committee on Poliomyelitis Eradication. Recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec 2009;84:289-90.
15. Marx A, Glass JD, Sutter RW. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev 2000;22:298-316. (Pubitemid 32116100)
16. Progress towards poliomyelitis eradication - Nigeria, 1996-1998. Wkly Epidemiol Rec 1997;74:121-4.
17. Vaccine-derived polioviruses detected worldwide, January 2008-June 2009. Wkly Epidemiol Rec 2009;84:390-6.
18. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587-635.
19. Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science 2006;314:1150-3. (Pubitemid 44789046)
20. National Population Commission (NPC, Nigeria) and ORC Macro. Nigeria demographic and health survey 2003. Calverton, MD: National Population Commission and ORC Macro, 2004. (Accessed May 28, 2010, at http://www. measuredhs.com/pubs/pdf/FR148/00FrontMatter.pdf.)
21. Legal notice on publication of the 2006 census report. Lagos: National Population Commission, Federal Republic of Nigeria, 2007. (Accessed May 28, 2010, at http://www.population.gov.ng/pop-figure.pdf.)
22. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis 1991;13:926-39.
23. Minor P. Poliovirus. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven, 1997:555-74.
24. Gelfand HM, Leblanc DR, Fox JP, Conwell DP. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 1957;65:367-85.
25. Estívariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island - Indonesia, 2005. J Infect Dis 2008;197:347-54.
26. Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006;26:1471-505.
27. Engagement and oversight of political and traditional leaders in polio eradication in Nigeria. Geneva: Advisory Committee on Polio Eradication, November 2009. (Accessed May 28, 2010, at http://www.polioeradication.org/ content/meetings/ACPE-2009/Nigeria.pdf.)
28. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, November 2009. Wkly Epidemiol Rec 2010;85:1-12.